Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Clinical Trial ID NCT01435369

Rank	Title	Journal	Year	PubWeight™‹?›
1	Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.	Clin Cancer Res	2013	3.48
2	From genes to drugs: targeted strategies for melanoma.	Nat Rev Cancer	2012	2.46
3	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.	Trends Mol Med	2014	1.59
4	Pathways and therapeutic targets in melanoma.	Oncotarget	2014	1.17
5	Immune modulation for cancer therapy.	Br J Cancer	2014	1.15
6	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.	J Hematol Oncol	2016	1.12
7	New immunotherapies targeting the PD-1 pathway.	Trends Pharmacol Sci	2015	1.02
8	Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma.	Cancer J	2012	0.97
9	Checkpoint modulation in melanoma: an update on ipilimumab and future directions.	Curr Oncol Rep	2013	0.94
10	Clinical Development of Immune Checkpoint Inhibitors.	Biomed Res Int	2015	0.82
11	Targeting CD8+ T-cell tolerance for cancer immunotherapy.	Immunotherapy	2014	0.81
12	PD-1 and PD-L1 antibodies for melanoma.	Hum Vaccin Immunother	2014	0.80